Biomedical Advanced Research and Development Authority

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Biomedical Advanced Research and Development Authority sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 7 completed early-phase tilt top decile by trial count

Biomedical Advanced Research and Development Authority: 10 sponsored US clinical trials, none currently recruiting.

Biomedical Advanced Research and Development Authority sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is COVID-19, with 2 trials.

Top-decile sponsor footprint

Biomedical Advanced Research and Development Authority ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

10 total, page 1 of 1

ACTIVE NOT RECRUITING

Project REMOTE (REimagining Measurements and Operations of Translational Endpoints)

NCT06776367
ACTIVE NOT RECRUITING

Retail COVID-19 Study

NCT06761612
ACTIVE NOT RECRUITING Phase 2

Anthrax AV7909 Boost Evaluation Study

NCT05997264
COMPLETED Phase 2

Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59

NCT06560151
COMPLETED Phase 1

Sublingual Atropine Bioequivalence by Route of Administration (SABER)

NCT06366087
COMPLETED Phase 1

Sublingual vs IV Atropine Bioavailability Study

NCT04290039
COMPLETED Phase 2

BARDA Securing Anthrax Immunity For the Elderly

NCT03518125
COMPLETED Phase 2

Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59

NCT03497845
COMPLETED Phase 2

Panblok H7 Vaccine Adjuvanted With AS03 or MF59

NCT03283319
COMPLETED Phase 2

Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant

NCT02680002

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 6

Therapeutic Areas

COVID-19 2
Anthrax 1

How the Biomedical Advanced Research and Development Authority early-phase archive is shaped

10 indexed studies, none listed as recruiting (0% open); 7 completed (70%).

Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: COVID-19 (2 trials), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Biomedical Advanced Research and Development Authority: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Biomedical Advanced Research and Development Authority sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Biomedical Advanced Research and Development AuthorityAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Biomedical Advanced Research and Development Authority sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Biomedical Advanced Research and Development Authority sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Biomedical Advanced Research and Development Authority page

10 registered trials is a research-attention snapshot, not an endorsement of Biomedical Advanced Research and Development Authority or any single study.

  • None of Biomedical Advanced Research and Development Authority's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • COVID-19 is the condition Biomedical Advanced Research and Development Authority studies most, compare against other sponsors active in the same condition before evaluating a specific study. See COVID-19 trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Biomedical Advanced Research and Development Authority pipeline card: 10 registered trials from official public datasets.Report a data error.